HTG Molecular Diagnostics, Inc. Deferred Tax Assets, Valuation Allowance
HTG Molecular Diagnostics, Inc. had Deferred Tax Assets, Valuation Allowance of $59.81 million as of 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2023-03-30
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $59.81M.
- 2021-12-31: Deferred Tax Assets, Valuation Allowance $53.96M.
- 2020-12-31: Deferred Tax Assets, Valuation Allowance $48.63M.
- 2019-12-31: Deferred Tax Assets, Valuation Allowance $43.35M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2022-12-31 | $59.81M 10-K · filed 2023-03-30 |
| 2021-12-31 | $53.96M 10-K · filed 2023-03-30 |
| 2020-12-31 | $48.63M 10-K · filed 2022-03-29 |
| 2019-12-31 | $43.35M 10-K · filed 2021-03-25 |
| 2018-12-31 | $38.74M 10-K · filed 2020-03-25 |
| 2017-12-31 | $35.01M 10-K · filed 2019-03-07 |
| 2016-12-31 | $43.48M 10-K · filed 2018-03-23 |
| 2015-12-31 | $33.94M 10-K · filed 2017-03-23 |
| 2014-12-31 | $25.20M 10-K · filed 2016-03-25 |